Issue 01  ·  March 2026

BCI Policy, Commercial Landscape & Strategic Foresight

The forces shaping brain-computer interface adoption are moving faster than most boardrooms realise. This report maps the policy shifts, commercial manoeuvres, and strategic positions that will define the next decade of neurotechnology — before the window to act closes.

14 slides
6 country profiles
5 company case studies
3 action horizons
Executive Summary — Free Preview

Between January and March 2026, six developments reshaped the brain-computer interface landscape. China formalised its national BCI standards framework. Science Corp published peer-reviewed data on a 25,000-electrode retinal interface. Synchron completed its COMMAND pivotal trial for ALS communication. South Korea committed $38 million to a dedicated BCI research programme. Chile's constitutional neurological protections survived judicial review. And the European AI Act's neurotechnology provisions took effect.

$2.9B
Global BCI market (2024)
$13.9B
Projected by 2030 (CAGR 29.1%)
6
Countries with active BCI policy
Inflection China's National Medical Products Administration issued binding technical standards for implantable neural interfaces — the first enforceable national BCI device framework globally.
Momentum Science Corp's retinal neuroprosthesis demonstrated 25,000-electrode density in peer-reviewed trials, surpassing prior benchmarks by an order of magnitude.
Signal The European AI Act's neurotechnology clauses took legal effect in February 2026 — classifying consumer-facing BCI applications as high-risk.
Inflection Synchron's COMMAND pivotal trial demonstrated a fully implanted endovascular BCI enabling ALS patients to communicate independently for the first time.
Issue 01

Report available 30 March 2026

Free executive summary and full report purchase options will be available on release.

What's in the Full Report
01
BCI Development Highlights
Six events from Q1 2026 classified by signal type — inflection, momentum, or early signal.
02
Country Profiles
Deep analysis of China, USA, South Korea, Chile, EU, and Australia — regulatory posture, funding, and strategic intent.
03
Company Case Studies
Science Corp, Neuralink, Synchron, Paradromics, and Emotiv — assessed on technical approach, clinical progress, and commercial trajectory.
04
Policymaker Playbook
Five concrete steps for regulators and policy advisors — from governance sandboxes to neurorights frameworks.
05
The Emotion Economy
How affective computing and neural data will create new market categories — and the ethical boundaries that need to hold.
06
Action Plan
Three horizons of recommended action for policymakers, enterprise leaders, and investors — immediate, mid-term, and long-term.
About This Report

The Dargentic Intelligence Report is produced independently by Dargentic Pty Ltd. It is not sponsored, endorsed, or funded by any company, government, or institution mentioned within. All analysis represents the independent assessment of the Dargentic research team.

Back to dargentic.com →